Firefly Neuroscience, Inc. Common Stock

Day range

$0.90 – $0.97

Open

$0.93

Prev close

$0.92

Volume

105.98K

Market cap

$14.43M

Shares out

15.69M

P/E

—

P/S

8.02

P/B

0.98

P/FCF

—

ROE

-64.3%

ROA

-56.3%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Cfo departureSep 14, 2026

  On September 8, 2026, the board of directors ... terminated Paul Krzywicki as Chief Financial Officer of the Company, effective September 24, 2026. Mr. Krzywicki's termination was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

• Charter amendmentAug 7, 2026

  Amendment No. 2 of Amended and Restated Certificate of Incorporation, As Amended...to decrease the total number of authorized shares from 5,001,000,000 to 101,000,000, consisting of (i) 100,000,000 shares of Common Stock, and (ii) 1,000,000 shares of preferred stock.

• Deal withdrawalJun 26, 2026

  On June 25, 2026, the Company and the Investor mutually agreed in writing to terminate the Purchase Agreement, pursuant to Section 5.3 thereof, with such termination effective as of June 25, 2026.

• Private placementMay 12, 2026

  On May 6, 2026, Firefly Neuroscience, Inc., a Delaware corporation (the "Company"), entered into a securities purchase agreement (the "Purchase Agreement") with an accredited investor (the "Investor"), pursuant to which the Company agreed to issue and sell to the Investor up to 666,667 units (each a "Unit" and, collectively, the "Units"), at a purchase price of $1.50 per Unit, for aggregate gross proceeds of up to $1,000,000. Each Unit consists of (i) one share of common stock; (ii) one common stock purchase warrant to purchase one share of Common Stock over five (5) years at an exercise price of $1.88 per share; and (iii) one common stock purchase warrant to purchase one share of Common Stock over five (5) years at an exercise price of $2.50 per share.

• Private placementApr 22, 2026

  On April 16, 2026, the Company consummated an Additional Closing under the Purchase Agreement, pursuant to which the Company issued 5,333,333 Units to an accredited investor (the 'Additional Investor', together with the Initial Investors, the 'Investors') at a total purchase price of $8,000,000. The Units were issued on the same terms and conditions as described in the Prior 8-K, including the price of $1.50 per Unit.

Days to cover

1.0

Short interest

1.1M

Avg volume

14.58M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
  positiveGlobeNewswire Inc.· Aug 5, 2026
• Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides
  positiveGlobeNewswire Inc.· Jul 28, 2026
• Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
  positiveGlobeNewswire Inc.· Jun 20, 2025
• Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.
  positiveBenzinga· May 5, 2025
• Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
  positiveGlobeNewswire Inc.· Feb 21, 2025